Literature DB >> 3534027

Intrauterine herpes simplex infection resembling mechanobullous disease in a newborn infant.

H H Harris, E Foucar, R D Andersen, T L Ray.   

Abstract

We present a case of transplacentally acquired intrauterine herpes simplex virus infection in a newborn delivered at 36 weeks' gestation by cesarean section because of intrauterine growth retardation and maternal preeclampsia. The mother experienced a single episode of serotype 2 herpes progenitalis at 14 weeks' gestation. At birth the infant manifested clinical findings of herpes simplex virus infection, which resembled epidermolysis bullosa and aplasia cutis congenita. Preexisting cutaneous lesions and intact fetal membranes at delivery strongly support a transplacentally acquired intrauterine herpes simplex virus infection. Repeated Tzanck smears, viral cultures, and immunohistochemical studies of the skin were required to confirm the diagnosis. Intrauterine herpes simplex virus infection is associated with significant morbidity and mortality but responds to antiviral therapy. Therefore this diagnosis must be considered in the neonate born with bullous or eroded skin lesions.

Entities:  

Mesh:

Year:  1986        PMID: 3534027     DOI: 10.1016/s0190-9622(86)70285-5

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  A report of three cases and review of intrauterine herpes simplex virus infection.

Authors:  Lucila Marquez; Moise L Levy; Flor M Munoz; Debra L Palazzi
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

2.  Aplasia cutis congenita: Two cases of non-scalp lesions.

Authors:  Tarek A Abulezz; Mahmoud A Shalkamy
Journal:  Indian J Plast Surg       Date:  2009-07

3.  A case of systemic aplasia cutis congenita: a newly recognized syndrome?

Authors:  Tokio Sugiura; Masanori Kouwaki; Shusuke Kiyosawa; Yoshie Sasada; Matsuyoshi Maeda; Kenji Goto; Norihisa Koyama
Journal:  Eur J Pediatr       Date:  2007-05-23       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.